On Aug. 30, 2018, the U.S. FDA approved doravirine as a separate formulation for use with ART and in a fixed-dose combination with generic tenofovir DF and lamivudine (3TC).
After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.
The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.
On July 17, 2018 the U.S. Food and Drug Administration approved Symtuza, a four-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Adherence to HIV care visits was associated more with mental health conditions before starting antiretroviral treatment than with recent depressive symptoms, while a detectable viral load was related to such symptoms.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.
Researchers found that heavy marijuana use increased the risk for complications of cardiovascular disease -- including heart attack and stroke -- regardless of whether the study participants also smoked tobacco and regardless of the presence of other...
As more people start HIV treatment, researchers are exploring ways to cut costs. Single tablets can be replaced by a few pills comprising cheaper generic drugs.
Researchers found that people taking common combinations of HIV drugs had increases in weight and body mass index, and those who were relatively thin or older prior to starting therapy were most likely to gain weight.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes.